IMMUNITYBIO, INC. (IBRX) Total liabilities 2016–2025
IMMUNITYBIO, INC. (IBRX) total liabilities at each fiscal year-end, per SEC filings.
$1.0BFY2025 · since FY2016: $24.1M → $1.0B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.0B | +15.0% |
| FY2024 | $871.1M | -20.1% |
| FY2023 | $1.1B | +34.3% |
| FY2022 | $812.2M | +13.9% |
| FY2021 | $712.8M | +109.7% |
| FY2020 | $339.9M | +34.1% |
| FY2019 | $253.5M | +605.2% |
| FY2018 | $35.9M | +13.8% |
| FY2017 | $31.6M | +31.2% |
| FY2016 | $24.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More IBRX financial trends
IBRX RevenueIBRX Net incomeIBRX Net marginIBRX Gross profitIBRX Gross marginIBRX Operating incomeIBRX Operating marginIBRX Operating cash flowIBRX Free cash flowIBRX Capital expendituresIBRX Return on equityIBRX Stock buybacksIBRX Dividends paidIBRX Total assetsIBRX Shareholders’ equityIBRX overview →